Symbols / JSPR $1.34 -2.19%
JSPR Chart
About
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 37.50M |
| Enterprise Value | -11.70M | Income | -91.02M | Sales | — |
| Book/sh | 0.41 | Cash/sh | 1.82 | Dividend Yield | — |
| Payout | 0.00% | Employees | 27 | IPO | — |
| P/E | — | Forward P/E | -0.51 | PEG | — |
| P/S | — | P/B | 3.24 | P/C | — |
| EV/EBITDA | 0.13 | EV/Sales | — | Quick Ratio | 2.42 |
| Current Ratio | 2.59 | Debt/Eq | 14.72 | LT Debt/Eq | — |
| EPS (ttm) | -5.82 | EPS next Y | -2.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-18 | ROA | -72.92% |
| ROE | -191.12% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 27.98M |
| Shs Float | 21.87M | Short Float | 12.35% | Short Ratio | 5.98 |
| Short Interest | — | 52W High | 7.19 | 52W Low | 1.11 |
| Beta | 3.12 | Avg Volume | 683.01K | Volume | 167.82K |
| Target Price | $10.50 | Recom | None | Prev Close | $1.37 |
| Price | $1.34 | Change | -2.19% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.50
Mean price target
2. Current target
$1.34
Latest analyst target
3. DCF / Fair value
$-27.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.34
Low
$4.00
High
$20.00
Mean
$10.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-11 | main | RBC Capital | Sector Perform → Sector Perform | $4 |
| 2025-09-22 | main | Evercore ISI Group | Outperform → Outperform | $14 |
| 2025-09-22 | main | JMP Securities | Market Outperform → Market Outperform | $6 |
| 2025-09-22 | main | BTIG | Buy → Buy | $7 |
| 2025-08-15 | main | UBS | Buy → Buy | $25 |
| 2025-07-08 | down | BMO Capital | Outperform → Market Perform | $4 |
| 2025-07-08 | main | JMP Securities | Market Outperform → Market Outperform | $12 |
| 2025-07-08 | main | Evercore ISI Group | Outperform → Outperform | $20 |
| 2025-07-07 | down | William Blair | Outperform → Market Perform | — |
| 2025-07-07 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-07-07 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2025-07-07 | main | BTIG | Buy → Buy | $20 |
| 2025-05-15 | main | Oppenheimer | Outperform → Outperform | $65 |
| 2025-05-13 | main | UBS | Buy → Buy | $33 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-02-13 | init | UBS | — → Buy | $38 |
| 2025-01-10 | reit | JMP Securities | Market Outperform → Market Outperform | $70 |
| 2025-01-10 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-01-09 | main | RBC Capital | Outperform → Outperform | $48 |
| 2025-01-06 | main | JMP Securities | Market Outperform → Market Outperform | $70 |
- Support Test: Why JSPR stock attracts high net worth investors - 2025 Earnings Surprises & Technical Analysis for Trade Confirmation - Naître et grandir Sat, 07 Mar 2026 10
- Biotech Jasper Therapeutics brings mast cell focus to TD Cowen - Stock Titan ue, 24 Feb 2026 08
- $JSPR stock is up 22% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize hu, 04 Dec 2025 08
- Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance hu, 20 Nov 2025 08
- Jasper Therapeutics Slides As Insider Purchases Lose Another US$89k - simplywall.st Wed, 05 Nov 2025 08
- Jasper Therapeutics stock maintains Market Outperform rating at Citizens - Investing.com Wed, 03 Dec 2025 08
- Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference - GlobeNewswire ue, 24 Feb 2026 08
- Jasper Therapeutics (Nasdaq: JSPR) reports asthma data, clears BEACON drug review - Stock Titan ue, 02 Dec 2025 08
- Jasper Therapeutics Announces Proposed Public Offering Of Common Stock And Warrant - Nasdaq Fri, 19 Sep 2025 07
- Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade ue, 02 Dec 2025 08
- Jasper Therapeutics Reports Positive Phase 1b Study Results - TipRanks ue, 02 Dec 2025 08
- Jasper Therapeutics stock plunges after manufacturing issues derail clinical trials - Investing.com Mon, 07 Jul 2025 07
- Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance hu, 29 May 2025 07
- Jasper Therapeutics (Nasdaq: JSPR) to host Dec. 2 webinar on ETESIAN, BEACON studies - Stock Titan Mon, 01 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 41000 | 99630 | — | Purchase at price 2.43 per share. | MARTELL RONALD A | Chief Executive Officer | — | 2025-09-22 00:00:00 | D |
| 1 | 41000 | 99630 | — | Purchase at price 2.43 per share. | WIGGANS THOMAS G | Director | — | 2025-09-22 00:00:00 | I |
| 2 | 20000 | 48600 | — | Purchase at price 2.43 per share. | LUCAS SVETLANA | Director | — | 2025-09-22 00:00:00 | D |
| 3 | 41000 | 99630 | — | Purchase at price 2.43 per share. | SHIZURU JUDITH ANNE M.D., PH.D. | Director | — | 2025-09-22 00:00:00 | D |
| 4 | 900 | 6390 | — | Conversion of Exercise of derivative security at price 7.10 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-12-12 00:00:00 | D |
| 5 | 900 | 19899 | — | Sale at price 22.11 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-12-12 00:00:00 | D |
| 6 | 900 | 6390 | — | Conversion of Exercise of derivative security at price 7.10 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-09-12 00:00:00 | D |
| 7 | 900 | 19104 | — | Sale at price 21.23 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-09-12 00:00:00 | D |
| 8 | 900 | 6390 | — | Conversion of Exercise of derivative security at price 7.10 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-06-12 00:00:00 | D |
| 9 | 900 | 21740 | — | Sale at price 24.16 per share. | MAHAL JEETINDER SINGH | Chief Operating Officer | — | 2024-06-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -74.87M | -67.20M | -63.15M | -42.73M |
| TotalUnusualItems | 0.00 | -557.00K | 12.93M | 6.28M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -557.00K | 12.93M | 6.28M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -71.27M | -64.47M | -37.69M | -30.64M |
| ReconciledDepreciation | 1.37M | 1.11M | 975.00K | 377.00K |
| EBITDA | -74.87M | -67.75M | -50.22M | -36.46M |
| EBIT | -76.24M | -68.86M | -51.20M | -36.83M |
| NetInterestIncome | 5.06M | 5.20M | 701.00K | |
| InterestIncome | 5.06M | 5.20M | 701.00K | |
| NormalizedIncome | -71.27M | -63.91M | -50.61M | -36.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -71.27M | -64.47M | -37.69M | -30.64M |
| TotalExpenses | 76.24M | 68.86M | 51.20M | 36.83M |
| TotalOperatingIncomeAsReported | -76.24M | -68.86M | -51.20M | -36.83M |
| DilutedAverageShares | 14.58M | 10.44M | 3.65M | 1.14M |
| BasicAverageShares | 14.58M | 10.44M | 3.65M | 1.14M |
| DilutedEPS | -4.89 | -6.18 | -10.30 | -26.90 |
| BasicEPS | -4.89 | -6.18 | -10.30 | -26.90 |
| DilutedNIAvailtoComStockholders | -71.27M | -64.47M | -37.69M | -30.64M |
| NetIncomeCommonStockholders | -71.27M | -64.47M | -37.69M | -30.64M |
| NetIncome | -71.27M | -64.47M | -37.69M | -30.64M |
| NetIncomeIncludingNoncontrollingInterests | -71.27M | -64.47M | -37.69M | -30.64M |
| NetIncomeContinuousOperations | -71.27M | -64.47M | -37.69M | -30.64M |
| PretaxIncome | -71.27M | -64.47M | -37.69M | -30.64M |
| OtherIncomeExpense | -88.00K | -803.00K | 12.81M | 6.20M |
| OtherNonOperatingIncomeExpenses | -88.00K | -246.00K | -115.00K | -80.00K |
| SpecialIncomeCharges | 0.00 | 18.00K | 5.72M | 9.28M |
| RestructuringAndMergernAcquisition | 0.00 | -18.00K | -5.72M | -9.28M |
| GainOnSaleOfSecurity | -575.00K | 7.20M | -3.00M | |
| NetNonOperatingInterestIncomeExpense | 5.06M | 5.20M | 701.00K | |
| InterestIncomeNonOperating | 5.06M | 5.20M | 701.00K | |
| OperatingIncome | -76.24M | -68.86M | -51.20M | -36.83M |
| OperatingExpense | 76.24M | 68.86M | 51.20M | 36.83M |
| ResearchAndDevelopment | 55.82M | 51.78M | 34.63M | 25.42M |
| SellingGeneralAndAdministration | 20.42M | 17.08M | 16.57M | 11.41M |
| GeneralAndAdministrativeExpense | 20.42M | 17.08M | 16.57M | 11.41M |
| OtherGandA | 20.42M | 17.08M | 16.57M | 11.41M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 15.02M | 11.16M | 3.80M | 3.79M |
| ShareIssued | 15.02M | 11.16M | 3.80M | 3.79M |
| TotalDebt | 1.81M | 2.79M | 3.65M | 2.88M |
| TangibleBookValue | 61.67M | 78.44M | 35.99M | 69.52M |
| InvestedCapital | 61.67M | 78.44M | 35.99M | 69.52M |
| WorkingCapital | 60.57M | 76.56M | 34.67M | 79.81M |
| NetTangibleAssets | 61.67M | 78.44M | 35.99M | 69.52M |
| CapitalLeaseObligations | 1.81M | 2.79M | 3.65M | 2.88M |
| CommonStockEquity | 61.67M | 78.44M | 35.99M | 69.52M |
| TotalCapitalization | 61.67M | 78.44M | 35.99M | 69.52M |
| TotalEquityGrossMinorityInterest | 61.67M | 78.44M | 35.99M | 69.52M |
| StockholdersEquity | 61.67M | 78.44M | 35.99M | 69.52M |
| RetainedEarnings | -240.87M | -169.60M | -105.14M | -67.45M |
| AdditionalPaidInCapital | 302.54M | 248.04M | 141.12M | 136.96M |
| CapitalStock | 2.00K | 1.00K | 0.00 | 4.00K |
| CommonStock | 2.00K | 1.00K | 0.00 | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 18.23M | 16.45M | 12.37M | 24.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.99M | 4.08M | 5.31M | 16.12M |
| OtherNonCurrentLiabilities | 2.26M | 2.26M | 2.36M | 600.00K |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 0.00 | 150.00K | 7.35M | |
| EmployeeBenefits | 0.00 | 9.00K | 19.00K | |
| TradeandOtherPayablesNonCurrent | 0.00 | 24.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 724.00K | 1.81M | 2.79M | 2.38M |
| LongTermCapitalLeaseObligation | 724.00K | 1.81M | 2.79M | 2.38M |
| LongTermProvisions | 18.00K | 5.74M | ||
| CurrentLiabilities | 15.24M | 12.37M | 7.07M | 8.02M |
| OtherCurrentLiabilities | 597.00K | 317.00K | 194.00K | 785.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.09M | 972.00K | 865.00K | 505.00K |
| CurrentCapitalLeaseObligation | 1.09M | 972.00K | 865.00K | 505.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.10M | 1.77M | 1.59M | 1.15M |
| PayablesAndAccruedExpenses | 10.45M | 9.32M | 4.42M | 5.58M |
| CurrentAccruedExpenses | 6.42M | 5.17M | 2.65M | 1.66M |
| Payables | 4.03M | 4.15M | 1.77M | 3.92M |
| AccountsPayable | 4.03M | 4.15M | 1.77M | 3.92M |
| TotalAssets | 79.90M | 94.89M | 48.36M | 93.65M |
| TotalNonCurrentAssets | 4.09M | 5.95M | 6.63M | 5.82M |
| OtherNonCurrentAssets | 1.24M | 1.76M | 1.18M | 990.00K |
| NetPPE | 2.85M | 4.19M | 5.45M | 4.83M |
| AccumulatedDepreciation | -3.81M | -2.46M | -1.35M | -377.00K |
| GrossPPE | 6.66M | 6.65M | 6.81M | 5.21M |
| Leases | 2.71M | 2.48M | 2.48M | 2.06M |
| OtherProperties | 3.02M | 3.44M | 3.59M | 2.72M |
| MachineryFurnitureEquipment | 922.00K | 737.00K | 737.00K | 438.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 75.81M | 88.94M | 41.73M | 87.83M |
| OtherCurrentAssets | 646.00K | 295.00K | 364.00K | 369.00K |
| PrepaidAssets | 3.53M | 1.51M | 2.20M | 2.21M |
| Receivables | 0.00 | 250.00K | 913.00K | 548.00K |
| OtherReceivables | 663.00K | 150.00K | ||
| TaxesReceivable | 0.00 | 250.00K | 250.00K | 548.00K |
| CashCashEquivalentsAndShortTermInvestments | 71.64M | 86.89M | 38.25M | 84.70M |
| CashAndCashEquivalents | 71.64M | 86.89M | 38.25M | 84.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -63.15M | -52.33M | -46.43M | -36.11M |
| IssuanceOfCapitalStock | 47.20M | 101.48M | 0.00 | 10.75M |
| CapitalExpenditure | -552.00K | -267.00K | -576.00K | -2.43M |
| EndCashPosition | 72.05M | 87.30M | 38.67M | 85.05M |
| BeginningCashPosition | 87.30M | 38.67M | 85.05M | 20.18M |
| ChangesInCash | -15.25M | 48.64M | -46.38M | 64.86M |
| FinancingCashFlow | 47.88M | 100.97M | 55.00K | 100.97M |
| CashFlowFromContinuingFinancingActivities | 47.88M | 100.97M | 55.00K | 100.97M |
| NetOtherFinancingCharges | -960.00K | 89.98M | ||
| ProceedsFromStockOptionExercised | 689.00K | 452.00K | 55.00K | 236.00K |
| NetPreferredStockIssuance | 0.00 | 10.75M | ||
| PreferredStockIssuance | 0.00 | 10.75M | ||
| NetCommonStockIssuance | 47.20M | 101.48M | 0.00 | |
| CommonStockIssuance | 47.20M | 101.48M | 0.00 | |
| InvestingCashFlow | -532.00K | -267.00K | -576.00K | -2.43M |
| CashFlowFromContinuingInvestingActivities | -532.00K | -267.00K | -576.00K | -2.43M |
| NetPPEPurchaseAndSale | -532.00K | -267.00K | -576.00K | -2.43M |
| SaleOfPPE | 20.00K | 0.00 | ||
| PurchaseOfPPE | -552.00K | -267.00K | -576.00K | -2.43M |
| OperatingCashFlow | -62.60M | -52.07M | -45.86M | -33.68M |
| CashFlowFromContinuingOperatingActivities | -62.60M | -52.07M | -45.86M | -33.68M |
| ChangeInWorkingCapital | 173.00K | 5.10M | -649.00K | 1.62M |
| ChangeInOtherCurrentLiabilities | -973.00K | -945.00K | 1.13M | -317.00K |
| ChangeInOtherCurrentAssets | 523.00K | -584.00K | -114.00K | -347.00K |
| ChangeInPayablesAndAccruedExpense | 2.75M | 5.20M | -1.31M | 3.90M |
| ChangeInAccruedExpense | 2.87M | 2.82M | 836.00K | 959.00K |
| ChangeInPayable | -122.00K | 2.38M | -2.15M | 2.94M |
| ChangeInAccountPayable | -122.00K | 2.38M | -2.15M | 2.94M |
| ChangeInPrepaidAssets | -2.12M | 767.00K | 312.00K | -2.21M |
| ChangeInReceivables | 0.00 | 663.00K | -663.00K | 600.00K |
| OtherNonCashItems | 491.00K | 401.00K | -5.39M | -9.09M |
| StockBasedCompensation | 6.62M | 5.21M | 4.09M | 1.05M |
| DepreciationAmortizationDepletion | 1.37M | 1.11M | 975.00K | 377.00K |
| DepreciationAndAmortization | 1.37M | 1.11M | 975.00K | 377.00K |
| OperatingGainsLosses | 11.00K | 575.00K | -7.20M | 3.00M |
| GainLossOnInvestmentSecurities | 575.00K | -7.20M | 3.00M | |
| GainLossOnSaleOfPPE | 11.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -71.27M | -64.47M | -37.69M | -30.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for JSPR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|